Prudential PLC Purchases 12,512 Shares of Amgen Inc. (NASDAQ:AMGN)

Prudential PLC increased its position in shares of Amgen Inc. (NASDAQ:AMGNGet Rating) by 33.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 49,509 shares of the medical research company’s stock after acquiring an additional 12,512 shares during the quarter. Prudential PLC’s holdings in Amgen were worth $11,138,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Dixon Hughes Goodman Wealth Advisors LLC acquired a new position in Amgen during the 4th quarter valued at approximately $26,000. Norwood Financial Corp purchased a new stake in shares of Amgen in the 4th quarter valued at $28,000. PYA Waltman Capital LLC purchased a new stake in shares of Amgen in the 4th quarter valued at $34,000. Joseph Group Capital Management purchased a new stake in shares of Amgen in the 4th quarter valued at $34,000. Finally, Econ Financial Services Corp purchased a new stake in shares of Amgen in the 4th quarter valued at $34,000. Hedge funds and other institutional investors own 79.01% of the company’s stock.

In other news, EVP Jonathan P. Graham sold 13,500 shares of the stock in a transaction dated Tuesday, May 10th. The shares were sold at an average price of $241.81, for a total value of $3,264,435.00. Following the completion of the sale, the executive vice president now directly owns 37,333 shares in the company, valued at $9,027,492.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.46% of the stock is owned by corporate insiders.

AMGN has been the topic of several recent research reports. Morgan Stanley dropped their price objective on shares of Amgen from $238.00 to $237.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 12th. TheStreet downgraded shares of Amgen from a “b+” rating to a “c+” rating in a report on Wednesday, April 27th. Mizuho upped their price objective on shares of Amgen from $202.00 to $208.00 in a report on Tuesday, May 10th. Wells Fargo & Company increased their price target on shares of Amgen from $210.00 to $250.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 9th. Finally, StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Monday. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus target price of $240.40.

AMGN traded up $1.25 during midday trading on Tuesday, hitting $245.12. 106,026 shares of the company traded hands, compared to its average volume of 3,365,221. The company has a current ratio of 1.44, a quick ratio of 1.09 and a debt-to-equity ratio of 39.31. The company has a market capitalization of $130.94 billion, a price-to-earnings ratio of 24.03, a PEG ratio of 1.69 and a beta of 0.58. Amgen Inc. has a 52-week low of $198.64 and a 52-week high of $258.45. The business has a 50 day simple moving average of $241.94 and a two-hundred day simple moving average of $227.93.

Amgen (NASDAQ:AMGNGet Rating) last issued its earnings results on Wednesday, April 27th. The medical research company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $4.22 by $0.03. The business had revenue of $6.24 billion during the quarter, compared to analysts’ expectations of $6.09 billion. Amgen had a net margin of 21.75% and a return on equity of 165.95%. During the same period in the prior year, the business earned $3.70 earnings per share. Equities research analysts anticipate that Amgen Inc. will post 17.49 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 8th. Stockholders of record on Tuesday, May 17th will be given a $1.94 dividend. This represents a $7.76 dividend on an annualized basis and a dividend yield of 3.17%. The ex-dividend date is Monday, May 16th. Amgen’s dividend payout ratio (DPR) is 76.38%.

Amgen Company Profile (Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNGet Rating).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.